Mersana Therapeutics Inc (MRSN) Stock Price, Quote & News

Company Profile

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and dev...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 498 0020

Website: www.mersana.com

Address:

840 Memorial Drive, Cambridge, United States

BEATWALLSTREET Oct. 22 at 6:12 PM

$MRSN did you buy that dip?

0 · Reply

BEATWALLSTREET Oct. 22 at 3:19 PM

$MRSN down to 6 ?

0 · Reply

macroaxis Oct. 18 at 4:56 PM

$MRSN - Pin Risk Eases as Growing Call Buying Signals Bullish Confidence in Mersana Therapeutics https://www.macroaxis.com/stock-options/MRSN/Mersana-Therapeutics?utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

David185018 Oct. 17 at 1:34 PM

$MRSN We haven’t even seen the real run yet.

0 · Reply

AAUS1 Oct. 17 at 7:15 AM

$MRSN Short interest heavy !! Should break out in few days !!

1 · Reply

KING00777 Oct. 16 at 6:48 PM

$MRSN I exited this stock. I feel market will crash and so will thsi

1 · Reply

KING00777 Oct. 16 at 5:26 PM

$MRSN Breaking 12 is most important. Let's buy some stocks

0 · Reply

AAUS1 Oct. 16 at 5:17 PM

$MRSN possible ?

0 · Reply

AAUS1 Oct. 16 at 4:46 PM

$MRSN we should to go 30 as minimum , not wait for big money trigger

0 · Reply

KING00777 Oct. 16 at 1:56 PM

$MRSN Can we break 12

1 · Reply

Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 7:00 AM EDT - 2 months ago

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results

Aug 6, 2025, 8:00 AM EDT - 2 months ago

Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025

Jul 24, 2025, 8:31 AM EDT - 3 months ago

Mersana Therapeutics Announces 1-for-25 Reverse Stock Split

Jun 2, 2025, 8:10 AM EDT - 5 months ago

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

May 20, 2025, 8:00 AM EDT - 5 months ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

May 15, 2025, 10:06 AM EDT - 5 months ago

Mersana Therapeutics, Inc. (MRSN) Q1 2025 Earnings Call Transcript

May 15, 2025, 9:20 AM EDT - 5 months ago

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 15, 2025, 7:00 AM EDT - 5 months ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

May 6, 2025, 7:00 AM EDT - 6 months ago

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

Apr 23, 2025, 10:12 AM EDT - 6 months ago

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

Apr 4, 2025, 4:05 PM EDT - 7 months ago

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Apr 1, 2025, 8:01 AM EDT - 7 months ago

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

Mar 3, 2025, 10:13 AM EST - 8 months ago

Mersana Therapeutics, Inc. (MRSN) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:01 AM EST - 8 months ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 24, 2025, 4:01 PM EST - 8 months ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

Jan 30, 2025, 8:00 AM EST - 9 months ago

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Jan 10, 2025, 12:49 PM EST - 10 months ago

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Jan 10, 2025, 6:02 AM EST - 10 months ago

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Jan 10, 2025, 6:00 AM EST - 10 months ago

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Dec 19, 2024, 7:17 AM EST - 11 months ago

Mersana Therapeutics: We're About To Find Out If ADC Platform Is More Tolerable

Nov 13, 2024, 1:26 PM EST - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 7:00 AM EST - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Nov 6, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

Aug 13, 2024, 12:55 PM EDT - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

May 9, 2024, 2:09 PM EDT - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q1 2024 Earnings Call Transcript

May 9, 2024, 6:59 AM EDT - 1 year ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

May 3, 2024, 4:30 PM EDT - 1 year ago

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 2, 2024, 8:00 AM EDT - 1 year ago

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

Feb 28, 2024, 2:10 PM EST - 1 year ago

Mersana Therapeutics, Inc. (MRSN) Q4 2023 Earnings Call Transcript

Feb 28, 2024, 7:00 AM EST - 1 year ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 21, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

Feb 1, 2024, 8:00 AM EST - 1 year ago

Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology Conference

Jan 5, 2024, 8:01 AM EST - 1 year ago

Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 7, 2023, 1:34 PM EST - 2 years ago

Mersana Therapeutics, Inc. (MRSN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:00 AM EST - 2 years ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

Oct 31, 2023, 4:30 PM EDT - 2 years ago

Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023

Oct 31, 2023, 8:00 AM EDT - 2 years ago

Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056

Sep 6, 2023, 7:00 AM EDT - 2 years ago

Mersana Therapeutics Announces Changes in Leadership

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Mersana Therapeutics Announces Second Quarter 2023 Financial Results

Jul 27, 2023, 7:06 AM EDT - 2 years ago

Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic Reprioritization

Jun 27, 2023, 5:45 AM EDT - 2 years ago

MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.

Jun 15, 2023, 8:03 AM EDT - 2 years ago

US FDA puts Mersana Therapeutics' ovarian cancer drug studies on partial hold

BEATWALLSTREET Oct. 22 at 6:12 PM

$MRSN did you buy that dip?

0 · Reply

BEATWALLSTREET Oct. 22 at 3:19 PM

$MRSN down to 6 ?

0 · Reply

macroaxis Oct. 18 at 4:56 PM

0 · Reply

David185018 Oct. 17 at 1:34 PM

$MRSN We haven’t even seen the real run yet.

0 · Reply

AAUS1 Oct. 17 at 7:15 AM

$MRSN Short interest heavy !! Should break out in few days !!

1 · Reply

KING00777 Oct. 16 at 6:48 PM

$MRSN I exited this stock. I feel market will crash and so will thsi

1 · Reply

KING00777 Oct. 16 at 5:26 PM

$MRSN Breaking 12 is most important. Let's buy some stocks

0 · Reply

AAUS1 Oct. 16 at 5:17 PM

$MRSN possible ?

0 · Reply

AAUS1 Oct. 16 at 4:46 PM

$MRSN we should to go 30 as minimum , not wait for big money trigger

0 · Reply

KING00777 Oct. 16 at 1:56 PM

$MRSN Can we break 12

1 · Reply

David185018 Oct. 16 at 12:40 PM

$MRSN today?

0 · Reply

winners18 Oct. 16 at 12:47 AM

$MRSN https://www.fiercebiotech.com/biotech/boehringer-ingelheim-digs-adcs-offering-nearly-1b-license-cancer-prospect-koreas-aimedbio

0 · Reply

winners18 Oct. 16 at 12:46 AM

$MRSN adc hot again https://stocktwits.com/winners18/message/632506229

0 · Reply

AAUS1 Oct. 15 at 7:34 PM

$MRSN Been trying to break $11 , let it to run for $50 minimum , there will not be sellers after it breaks.

1 · Reply

KING00777 Oct. 15 at 4:26 PM

$MRSN Why in red suddenly..

1 · Reply

KING00777 Oct. 15 at 2:02 PM

$MRSN can this hit 11 today?

1 · Reply

David185018 Oct. 15 at 1:49 PM

$MRSN ultra bullish

1 · Reply

David185018 Oct. 15 at 8:19 AM

$MRSN $20 EOY. Easy.” 💥

1 · Reply

KING00777 Oct. 14 at 8:40 PM

$MRSN Is there any news? Any upcoming catalysts?

1 · Reply

David185018 Oct. 14 at 7:30 AM

$MRSN Let’s not go below $10 ever again.

0 · Reply

DanJfly Oct. 13 at 6:58 PM

$MRSN average of $8.02. 30% up but waiting for some big gains here. Show me $50

1 · Reply

DanJfly Oct. 13 at 6:20 PM

$MRSN she broke $10

0 · Reply

Market Cap	49.01M
Revenue (ttm)	40.50M
Net Income (ttm)	-69.19M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-170.84%
Debt to Equity Ratio	-0.33

Volume	30,400
Avg Vol	64,678
Day's Range	N/A - N/A
Shares Out	4.99M
Stochastic %K	43%
Beta	0.90
Analysts	Strong Sell
Price Target	$28.29